Abstract

Sputum and plasma adiponectin levels in clinically stable adult cystic fibrosis patients with CFTRI1234V mutation Background: Cystic fibrosis (CF) lung disease is associated with chronic inflammation leading to a decrease in lung function. Adiponectin is a predominantly anti-inflammatory adipokine that may have a role in CF lung. Aims: To determine sputum and plasma adiponectin levels in clinically stable adults CF patients with CFTR I1234 V mutation, compared to plasma adiponectin levels in healthy controls and to investigate their correlations with lung function in patients with CF. Methods: A cross-sectional study comprises 17 CF patients and 18 healthy controls. Adiponectin levels were measured by magnetic bead-based multiplex assay. Results: The mean age of adult CF patients was 22.9 years± 3.8 (18-30) and13/17 (76.5%) CF patients had pancreatic sufficiency. The mean BMI in healthy controls was higher than BMI in CF patients but statistically insignificant. The mean sputum adiponectin level was significantly lower than plasma adiponectin levels in CF patients and healthy controls (p adiponectin levels between CF patients and healthy controls. The mean sputum adiponectin level was higher in CF patients with pancreatic insufficiency versus CF patients with pancreatic sufficiency (p Conclusions: Sputum adiponectin may provide a minimally invasive tool in the assessment of an inflammatory status in CF patients.

Highlights

  • Cystic fibrosis (CF) lung disease is associated with chronic inflammation leading to progress in lung function

  • The characteristics of CF adults patients and healthy control subjects are presented in Table1.The mean age of adult CF patients was 22.9 ± 3.8 years (18-30) and 13/17 (76.47%) CF patients had pancreatic sufficiency, one had CF-related diabetes mellitus (CF-DM) and none of CF patients had CFrelated liver disease

  • We investigated whether stable adult CF patients with mild cystic fibrosis transmembrane conductance regulator (CFTR) genotype with pancreatic sufficiency modulated sputum and plasma adiponectin levels

Read more

Summary

Introduction

Cystic fibrosis (CF) lung disease is associated with chronic inflammation leading to progress in lung function. This study aims to determine total sputum and total plasma adiponectin levels in clinically stable adults CF patients with CFTR I1234V mutation, compared to plasma adiponectin levels in healthy controls and to investigate their correlations with body mass index (BMI) and spirometry in patients with CF. The mean sputum adiponectin level was observed to be higher in CF patients with pancreatic insufficiency. Further larger study to address any difference in sputum and plasma adiponectin levels among CF patients with pancreatic sufficiency versus pancreatic insufficiency. Adiponectin may account in a number of metabolic processes, including glucose and fatty acid metabolism where its levels reduced with increasing obesity, type 2 diabetes, the and cardiovascular disease compared to healthy controls matched by BMI [15,16,17]. Its properties are mediated by specific receptors that are widely expressed with AdipoR1, AdipoR2, and T-cadherin being present on epithelial and endothelial pulmonary cells, expressing potentially a vital role in lung physiology [18,19]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.